Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 15, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 750,000 ordinary shares of 25 pence each.
- Purchase Price: 1,341.63 pence per share.
- Treasury Shares Held: 232,697,678 shares (post-transaction).
- Shares in Issue: 5,758,650,672 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase on December 15, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying 750,000 shares by 1,341.63 pence.
- Confirm the updated total share capital structure (5,758,650,672 issued shares vs. 232,697,678 treasury shares).
- Review the original shareholder authorization from the May 17, 2006 Annual General Meeting to understand the remaining buyback capacity.